Literature DB >> 9457628

Increased CSF tau protein in corticobasal degeneration.

K Mitani1, Y Furiya, T Uchihara, K Ishii, H Yamanouchi, H Mizusawa, H Mori.   

Abstract

Using a sensitive sandwich enzyme-linked immunosorbent assay (ELISA) method, we measured the concentration of total tau protein in the cerebrospinal fluid (CSF) from nine patients with corticobasal degeneration (CBD) in comparison with 12 normal control subjects in order to assess its diagnostic value. The CSF concentration of tau in patients with CBD (0.69, 0.20 ng/ml; mean, SD) was higher than that in, the normal controls (0.48, 0.14 ng/ml, P = 0.0076 unpaired t test). This increase in CBD patients may reflect widespread tau pathology in CBD, but should be interpreted with reserve as an aid to diagnosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9457628     DOI: 10.1007/s004150050173

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  5 in total

Review 1.  Corticobasal degeneration: a pathologically distinct 4R tauopathy.

Authors:  Naomi Kouri; Jennifer L Whitwell; Keith A Josephs; Rosa Rademakers; Dennis W Dickson
Journal:  Nat Rev Neurol       Date:  2011-04-12       Impact factor: 42.937

2.  Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease.

Authors:  A J Green; E J Thompson; G E Stewart; M Zeidler; J M McKenzie; M A MacLeod; J W Ironside; R G Will; R S Knight
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-06       Impact factor: 10.154

3.  CSF phospho-tau is independent of age, cognitive status and gender of neurological patients.

Authors:  Armin Scheurich; Peter P Urban; Nassrin Koch-Khoury; Andreas Fellgiebel
Journal:  J Neurol       Date:  2009-11-17       Impact factor: 4.849

Review 4.  CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease.

Authors:  K Blennow; E Vanmechelen; H Hampel
Journal:  Mol Neurobiol       Date:  2001 Aug-Dec       Impact factor: 5.682

5.  CSF tau and β-amyloid as biomarkers for mild cognitive impairment.

Authors:  Harald Hampel; Kaj Blennow
Journal:  Dialogues Clin Neurosci       Date:  2004-12       Impact factor: 5.986

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.